Advertisement
Screener

PHATHOM PHARMACEUTICALS, INC. (PHAT) Graph

PHAT Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $74.27M; Cost of revenue $15.10M; Research and development $7.81M; Selling, general and administrative $55.33M.
  • 2026-03-31: Revenue $58.30M; Cost of revenue $12.00M; Research and development $7.77M; Selling, general and administrative $54.01M.
  • 2025-12-31: Revenue $57.58M*; Cost of revenue $7.65M*; Research and development $7.49M*; Selling, general and administrative $48.37M*.
  • 2025-09-30: Revenue $49.50M; Cost of revenue $6.19M; Research and development $7.03M; Selling, general and administrative $51.56M.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

PHAT revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Revenue$74.27MCost of revenue$15.10MGross profit$59.18MOperating expenses$63.14MOperating income-$3.96MOther income, net-$24.00KResearch & development$7.81MSelling, general& administrative$55.33MNet income-$17.58M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$74.27M$15.10M$7.81M$55.33M$63.14M-$17.58M
2026-03-31$58.30M$12.00M$7.77M$54.01M$61.78M-$30.37M
2025-12-31$57.58M*$7.65M*$7.49M*$48.37M*$55.86M*$199.88M*
2025-09-30$49.50M$6.19M$7.03M$51.56M$58.59M-$29.97M
2025-06-30$39.50M$5.04M$9.08M$85.31M$94.39M-$75.81M
2025-03-31$28.52M$3.72M$9.18M$94.47M$103.66M-$94.32M
2024-09-30$16.35M$2.36M$8.69M$76.10M$84.79M-$85.58M
2024-06-30$7.32M$1.38M$7.38M$75.87M$83.25M-$91.45M
2024-03-31$1.91M$426.00K$9.43M$62.01M$71.44M-$82.85M
2023-09-30$0.00$0.00$12.26M$23.40M$35.66M-$43.24M
2023-06-30$0.00$0.00$12.76M$18.94M$31.70M-$40.97M
2023-03-31$0.00$0.00$11.48M$18.60M$30.08M-$37.81M
2022-09-30(m)(m)$19.02M(m)$42.53M-$51.09M
2022-06-30(m)(m)$18.82M(m)$45.36M-$50.92M
2022-03-31(m)(m)$17.66M(m)$37.91M-$40.66M
2021-09-30(m)(m)$16.61M(m)$33.14M-$36.66M
2021-06-30(m)(m)$21.60M(m)$35.32M-$36.55M
2021-03-31(m)(m)$20.58M(m)$33.58M-$34.84M
2020-12-31(m)(m)$41.65M(m)$52.44M-$53.72M
2020-09-30(m)(m)$25.77M(m)$32.83M-$34.10M
2020-06-30(m)(m)$14.86M(m)$20.02M-$21.10M
2020-03-31(m)(m)$15.87M(m)$20.38M-$20.14M
2019-12-31(m)(m)$12.70M(m)$15.69M-$98.01M
2019-09-30(m)(m)$4.47M(m)$6.28M-$68.11M
2019-06-30(m)(m)$2.77M(m)$83.01M-$87.76M
2019-03-31(m)(m)$429.00K(m)$1.23M-$1.25M
2018-12-31(m)(m)$14.00K(m)$451.00K-$484.00K
2018-09-30(m)(m)$6.00K(m)$268.00K-$290.00K
2018-06-30(m)(m)(m)(m)$255.00K-$260.00K
2018-03-31(m)(m)(m)(m)$251.00K-$254.00K

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2026-06-30$132.57M$27.09M$15.59M$109.34M$124.93M-$47.95M
2025-06-30$68.02M$8.76M$18.26M$179.79M$198.05M-$170.13M
2024-06-30$9.24M$1.80M$16.81M$137.88M$154.69M-$174.30M
2023-06-30$0.00$0.00$24.24M$37.54M$61.78M-$78.78M
2022-06-30(m)(m)$36.48M(m)$83.27M-$91.58M
2021-06-30(m)(m)$42.18M(m)$68.90M-$71.39M
2020-06-30(m)(m)$30.72M(m)$40.40M-$41.24M
2019-06-30(m)(m)$3.20M(m)$84.24M-$89.01M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesNet income
2025-09-30$117.53M$14.95M$25.29M$231.35M$256.63M-$200.10M
2024-09-30$25.59M$4.16M$25.50M$213.98M$239.48M-$259.88M
2023-09-30$0.00$0.00$36.51M$60.93M$97.44M-$122.02M
2022-09-30(m)(m)$55.49M(m)$125.80M-$142.68M
2021-09-30(m)(m)$58.79M(m)$102.04M-$108.06M
2020-09-30(m)(m)$56.49M(m)$73.23M-$75.35M
2019-09-30(m)(m)$7.67M(m)$90.52M-$157.13M
2018-09-30(m)(m)$6.00K(m)$774.00K-$804.00K

Revenue and expense 12 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2025-12-31$175.11M$22.60M$32.78M$279.72M$312.50M$0.00-$221.25K
2024-12-31$55.25M$7.97M$34.08M$290.66M$324.75M$0.00-$334.33K
2023-12-31$682.00K$167.00K$49.90M$117.93M$167.83M$0.00-$201.59K
2022-12-31$0.00$0.00$71.44M$101.00M$172.44M$0.00-$197.72M
2021-12-31(m)(m)$72.34M(m)$135.08M$0.00-$143.88M
2020-12-31(m)(m)$98.15M(m)$125.67M$0.00-$129.07M
2019-12-31(m)(m)$20.37M(m)$106.22M$0.00-$255.13M
2018-12-31(m)(m)$20.00K(m)$1.23M$0.00-$1.29M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Altimmune, Inc. (ALT)United States$0.593B-6.43
Monopar Therapeutics (MNPR)United States$0.598B-34.82
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
CorMedix Inc. (CRMD)United States$0.605B3.25
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Evolus, Inc. (EOLS)United States$0.519B-13.32
Neurogene Inc. (NGNE)$0.625B-4.46